RxDoctor Payments Data

Katherine Homrok, MD

Family Medicine · Pittsburgh, PANPI 1376541375

Payments from drug & device makers

$2,282in general payments, 2019–2025

Across 131 payments — averaging $17.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$564
  • Merck$293
  • Viiv Healthcare Company$268
  • Novo Nordisk$245
  • AbbVie$141
  • GSK$99
  • plus $672 from 20 others

What the payments were for

  • Food & beverage$2,282100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,282 in reported general payments places this provider in the 75th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$451
Medicare patients
15
Services billed
22

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide74$72,401
XareltoRivaroxaban63$45,996
EliquisApixaban49$34,600
JardianceEmpagliflozin28$20,068
EntrestoSacubitril/Valsartan13$14,351
MounjaroTirzepatide12$12,620
Breo ElliptaFluticasone/Vilanterol25$11,325
JanuviaSitagliptin Phosphate14$10,951
Bydureon BciseExenatide Microspheres11$8,953
MyrbetriqMirabegron17$7,163
Stiolto RespimatTiotropium Br/Olodaterol Hcl14$6,795
Lantus SolostarInsulin Glargine,hum.Rec.Anlog40$4,582
Varenicline Tartrate14$4,317
Tiotropium Bromide14$3,174
Insulin Lispro Kwikpen U-100Insulin Lispro15$2,283

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$245$72,40174 claims
PfizerEliquis$38$34,60049 claims
NovartisEntresto$45$14,35113 claims
GSKBreo Ellipta$99$11,32525 claims
MerckJanuvia$293$10,95114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →